In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alcami Corporation

Latest From Alcami Corporation

Biotechnology Fundraising Reflects Bigger Start-Ups, Fewer IPOs in 2005

Fundraising among private biotechs has evened out this year, with larger early rounds reflecting the renewed "think-big" strategy of some start ups, and larger late rounds a consequence of less receptive IPO markets.

BioPharmaceutical Business Strategies

Schering-Plough, Novartis and Foradil: Measuring the Need for New Products

Schering's willingness to take over the marketing responsibilities for Novartis's Foradil respiratory drug, which has been largely superseded by combination products, to some degree measures the depths of Schering's troubles. But it also indicates the kinds of competition small-company in-licensers are likely to face. A whole industry of in-licensing focused players has grown up to sell the non-core products of Big Pharma: if Schering is any indication, the competition for these products is likely to get even more intense.

BioPharmaceutical Strategy

Lilly & Boehringer: When You Gotta Partner, You Gotta Partner

Lilly's co-promotion with Boehringer Ingelheim of duloxetine is the first time the American company has signed a major marketing deal for one of its own products. The company notes the collaboration is part of its broad commitment to partnering and that the market is intensely competitive. But the choice of duloxetine--the launch of which may be delayed indefinitely because of manufacturing problems--also represents Lilly's lowest-risk option for subsidizing the launches, and maximizing the returns from, potentially eight new products over the next few years.


The Drug Industry's Real Post-Genomics Problem: Financing the Pipeline

At iO Pharmaceuticals, two former Genentech executives aim to do for Big Pharma what Genentech, with its creative financing techniques, did for itself. By setting up a clinical development company, they plan to create off-P&L financing structures which will allow drug companies to develop more products without decreasing earnings.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Services
  • Contract Manufacturing Organization
  • Pharmaceuticals
    • Specialty Pharmaceuticals